Manufacturer record
Pragti Remedies: regulatory record
Last checked 20 September 2026. Source: CDSCO monthly NSQ alerts and state drug-testing laboratories
3 batches manufactured by Pragti Remedies (Assam) were declared Not of Standard Quality between April 2023 and April 2024. Records are batch-specific findings by government laboratories as published in CDSCO's monthly alerts; where a company has stated that a flagged batch was counterfeit, that statement is noted when reported.
Records by type
3 records linked to Pragti Remedies in the datasets we hold. A zero means nothing is on record in those datasets, not that nothing ever happened. What the labels mean.
CDSCO drug alerts: Not of Standard Quality and spurious drugs
Scope. A company appearing here is not a finding that its products are unsafe. Regulatory actions can apply to one batch, one formulation, one period or one state. Always check the linked government document for the current position, and tell us if something is out of date. How we label records.
Flagged batches per year
All flagged batches
| Product | Batch | Reason declared NSQ | Tested by | Alert |
|---|---|---|---|---|
| Cefixime Trihydrate with Lactic Acid Bacillus Tablets I.P. (Presef-200 LB Tablets) | BHCJ-009Mfg 2022-11 · Exp 2024-10 | Identification & Assay of Cefixime and Gram Positive endospore bearing rod shaped bacterium. The sample deemed to be Spurious.Assay | CDL KolkataCDSCO lab | Apr 2024 |
| Cefixime Trihydrate with Lactic Acid Bacillus Tablets LP. (Presef 200 "LB Tablets) ?Serial No. 14 of NSQ alert of April, 2024" | BHCJ-009Mfg 2022-11 · Exp 2024-10 | Not applicableOther | Not applicableState lab | Apr 2024 |
| Cefixime, Ofloxacin and Lactic Acid Bacillus Tablets (C- Cef OLB Tablets) | SLH-2101Mfg 2022-01 · Exp 2023-12 | Identification and Assay of Cefixime, Ofloxacin and Lactic Acid BacillusAssay | RDTL ChandigarhState lab | Apr 2023 |
Right of reply. Manufacturers may submit a response or a laboratory re-test result; it is published unedited alongside this record. Submit a response.